Moderna rose nearly 7% and Novavax gained more than 20% during the week ended Oct. 11, while Viatris agreed to acquire Pacira BioSciences for $1.65 billion.
BofA Securities lowered its price target to $9 from $25 after CMS reduced a major California Medicare Advantage contract’s rating to 3.5 stars from 4 stars.
